{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:03:07Z","timestamp":1788832987488,"version":"build-2803163510"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>This case report explores the consequences of ruxolitinib via inhibition janus kinase 1 (JAK1) and JAK2 pathways in the context of fungal defense in a patient diagnosed with pulmonary coccidioidomycosis during ruxolitinib therapy for polycythemia vera. The patient experienced a relapse of pulmonary coccidioidomycosis after antifungal treatment was discontinued while continuing ruxolitinib use. This case illustrates the heightened risk of discontinuing antifungal therapy in endemic regions, emphasizing the critical need for continued monitoring. Furthermore, this case underscores the vital role of the JAK1 and JAK2 signaling cascade, particularly the interferon-gamma (INF-\u03b3)-JAK1 and JAK2-signal transducer and activator of transcription 1 (STAT) axis, in antifungal defense. Recent studies have revealed that the loss of function in JAK1 (but not JAK2), leads to impaired macrophage activation and reduced T-helper 1 (Th1) cell responses, thereby compromising the body's ability to fight off dimorphic fungi, such as <jats:italic>Coccidioides<\/jats:italic>. Other proposed fungal immune mechanisms in the JAK-STAT pathway are discussed. Clinicians tailoring JAK inhibitor treatment options for patients must be aware of the INF-\u03b3-JAK1-STAT pathway's pivotal role in antifungal defense.<\/jats:p>","DOI":"10.3389\/fmed.2025.1643068","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:25:44Z","timestamp":1760419544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A case displaying the importance of JAK1 and JAK2 gene transcription in antifungal defense against coccidioidomycosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Jennifer K.","family":"Priessnitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Colore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Nicolasora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib vs. standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","article-title":"Ruxolitinib vs. best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","volume":"9","author":"Passamonti","year":"2022","journal-title":"Lancet Haematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/jof10040264","article-title":"Disseminated histoplasmosis in a patient with myelofibrosis on ruxolitinib: a case report and review of the literature on ruxolitinib-associated invasive fungal infections","volume":"10","author":"Chiu","year":"2024","journal-title":"J Fungi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"ofaa167","DOI":"10.1093\/ofid\/ofaa167","article-title":"Coccidioidomycosis in patients treated with ruxolitinib","volume":"7","author":"Kusne","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jaci.2013.01.052","article-title":"Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis","volume":"131","author":"Sampaio","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1161\/ATVBAHA.110.207464","article-title":"Suppressors of cytokine signaling (SOCS) proteins and JAK\/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3","volume":"31","author":"Tamiya","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1093\/cid\/ciw360","article-title":"2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.2147\/IDR.S267997","article-title":"Tuberculosis in patients with primary myelofibrosis during ruxolitinib therapy: case series and literature review","volume":"13","author":"Peng","year":"2020","journal-title":"Infect Drug Resist."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib vs. best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00277-018-3242-8","article-title":"Infections associated with ruxolitinib: study in the French Pharmacovigilance database","volume":"97","author":"Sylvine","year":"2018","journal-title":"Ann Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ajh.24572","article-title":"Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients","volume":"92","author":"Polverelli","year":"2017","journal-title":"Am J Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cid\/ciab1026","article-title":"Incidence of invasive fungal infections in patients initiating ibrutinib and other small molecule kinase inhibitors-United States, July 2016-June 2019","volume":"75","author":"Gold","year":"2022","journal-title":"Clin Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/jof7121058","article-title":"Invasive fungal infections and targeted therapies in hematological malignancies","volume":"7","author":"Little","year":"2021","journal-title":"J Fungi"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00035-19","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","author":"Davis","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2049936121989548","DOI":"10.1177\/2049936121989548","article-title":"Risk of infection associated with targeted therapies for solid organ and hematological malignancies","volume":"8","author":"Ruiz-Camps","year":"2021","journal-title":"Ther Adv Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nri2939","article-title":"Immunity to fungal infections","volume":"11","author":"Romani","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3201\/eid2302.160505","article-title":"Risk factors for disseminated coccidioidomycosis, United States","volume":"23","author":"Odio","year":"2017","journal-title":"Emerg Infect Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.3390\/cancers13112611","article-title":"Untwining anti-tumor and immunosuppressive effects of JAK inhibitors-a strategy for hematological malignancies?","volume":"13","author":"Klein","year":"2021","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.3389\/fimmu.2018.03108","article-title":"Loss of JAK1 drives innate immune deficiency","volume":"9","author":"Witalisz-Siepracka","year":"2018","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.stem.2017.08.011","article-title":"Jak1 integrates cytokine sensing to regulate hematopoietic stem cell function and stress hematopoiesis","volume":"21","author":"Kleppe","year":"2017","journal-title":"Cell Stem Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e59675","DOI":"10.1371\/journal.pone.0059675","article-title":"Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans","volume":"8","author":"Park","year":"2013","journal-title":"PLoS ONE."},{"key":"B26","volume-title":"RINVOQ [package insert]","year":""},{"key":"B27","unstructured":"Gilead\n              Sciences & European Medicines Agency\n            \n          \n          Jyseleca, INN-filgotinib, Gilead Sciences, European Medicines Agency\n          \n          2022"},{"key":"B28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Pascual-Ramos V Connell C Gold D Chen A Shi H Shapiro A Pope J Schulze-Koops H. CG Incidence of infections in patients aged \u2265 50 years with RA and \u2265 1 additional cardiovascular risk factor: results from a phase 3b\/4 randomized safety study of tofacitinib vs. TNF inhibitors","volume":"73","author":"B\u0103l\u0103nescu","year":"2021","journal-title":"Am Coll Rhematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"152120","DOI":"10.1016\/j.semarthrit.2022.152120","article-title":"Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review","volume":"58","author":"Winthrop","year":"2023","journal-title":"Semin Arthritis Rheum."},{"key":"B32","unstructured":"Incyte sinks as itacitinib fails pivotal test in acute GVHD\n          \n          \n            \n              Taylor\n              NP\n            \n          \n          Fierce Biotech\n          \n          2020"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/nature06096","article-title":"Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome","volume":"448","author":"Minegishi","year":"2007","journal-title":"Nature."},{"key":"B34","article-title":"STAT3 hyper IgE syndrome","author":"Hsu","year":"2020"},{"key":"B35","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s10875-021-01051-1","article-title":"STAT3 Hyper-IgE Syndrome-an Update and Unanswered Questions","volume":"41","author":"Tsilifis","year":"2021","journal-title":"J Clin Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/imr.13312","article-title":"JAK\/STAT defects and immune dysregulation, and guiding therapeutic choices","volume":"322","author":"Chaimowitz","year":"2024","journal-title":"Immunol Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1182\/blood-2014-04-570101","article-title":"Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3","volume":"125","author":"Haapaniemi","year":"2015","journal-title":"Blood."},{"key":"B38","doi-asserted-by":"publisher","first-page":"770077","DOI":"10.3389\/fped.2022.770077","article-title":"STAT3 gain-of-function syndrome","volume":"10","author":"Vogel","year":"2022","journal-title":"Front Pediatr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaci.2022.09.002","article-title":"Monogenic early-onset lymphoproliferation and autoimmunity: natural history of STAT3 gain-of-function syndrome","volume":"151","author":"Leiding","year":"2023","journal-title":"J Allergy Clin Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"ofx202","DOI":"10.1093\/ofid\/ofx202","article-title":"Risks of ruxolitinib in STAT1 gain-of-function-associated severe fungal disease","volume":"4","author":"Zimmerman","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5114\/ceji.2022.114884","article-title":"Chronic mucocutaneous candidiasis, pancytopenia, and systemic mycosis in a patient with STAT1 gene mutation ineffectively treated with ruxolitinib","volume":"47","author":"Bazan-Socha","year":"2022","journal-title":"Cent Eur J Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20110958","article-title":"Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis","volume":"208","author":"Liu","year":"2011","journal-title":"J Exp Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3389\/fimmu.2019.01433","article-title":"STAT1 gain-of-function mutations cause high total STAT1 levels with normal dephosphorylation","volume":"10","author":"Zimmerman","year":"2019","journal-title":"Front Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood."},{"key":"B46","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10875-020-00943-y","article-title":"Stepwise reversal of immune dysregulation due to STAT1 gain-of-function mutation following ruxolitinib bridge therapy and transplantation","volume":"41","author":"Kayaoglu","year":"2021","journal-title":"J Clin Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s10875-022-01351-0","article-title":"Three adult cases of STAT1 gain-of-function with chronic mucocutaneous candidiasis treated with JAK inhibitors","volume":"43","author":"Borgstr\u00f6m","year":"2023","journal-title":"J Clin Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.jaci.2017.08.040","article-title":"Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations","volume":"141","author":"Vargas-Hern\u00e1ndez","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1007\/s10875-023-01528-1","article-title":"Neutrophils in STAT1 gain-of-function have a pro-inflammatory signature which is not rescued by JAK inhibition","volume":"43","author":"Parackova","year":"2023","journal-title":"J Clin Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/infdis\/jix522","article-title":"Oliveira Junior E, et al. Paracoccidioidomycosis associated with a heterozygous STAT4 mutation and impaired IFN-\u03b3 immunity","volume":"216","author":"Schimke","year":"2017","journal-title":"J Infect Dis."},{"key":"B51","unstructured":"U.S. Atlanta, GA\n          Centers for Disease Control and Prevention\n          Clinical Overview of Valley Fever\n          \n          2025"},{"key":"B52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1128\/JCM.02230-06","article-title":"Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis","volume":"45","author":"Saubolle","year":"2007","journal-title":"J Clin Microbiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1086\/521259","article-title":"Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America","volume":"45","author":"Wheat","year":"2007","journal-title":"Clin Infect Dis."},{"key":"B54","unstructured":"Clinical Overview of Histoplasmosis\n          \n          2025"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1128\/CVI.00071-07","article-title":"Detection of histoplasma antigen by a quantitative enzyme immunoassay","volume":"14","author":"Connolly","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1128\/CVI.00409-08","article-title":"Improved detection of Histoplasma antigenemia following dissociation of immune complexes","volume":"16","author":"Swartzentruber","year":"2009","journal-title":"Clin Vaccine Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1590\/0037-8682-0230-2017","article-title":"Brazilian guidelines for the clinical management of paracoccidioidomycosis","volume":"50","author":"Shikanai-Yasuda","year":"2017","journal-title":"Rev Soc Bras Med Trop."},{"key":"B58","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1590\/S0036-46652015000700008","article-title":"Lateral flow assay for cryptococcal antigen, an important advance to improve the continuum of HIV care and reduce cryptococcal meningitis-related mortality","volume":"57","author":"Vidal","year":"2015","journal-title":"Rev Inst Med Trop S\u00e3o Paulo."},{"key":"B60","first-page":"23","article-title":"Pneumocystis jiroveci pneumonia: a review of management in Human Immunodeficiency Virus (HIV) and non-HIV immunocompromised patients","volume-title":"Avicenna J Med.","author":"Ibrahim","year":"2023"},{"key":"B61","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4046\/trd.2020.0015","article-title":"Recent advances in the diagnosis and management of pneumocystis pneumonia","volume":"83","author":"Tasaka","year":"2020","journal-title":"Tuberc Respir Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0188860","DOI":"10.1371\/journal.pone.0188860","article-title":"Diagnostic performance of the (1-3)-\u03b2-D-glucan assay in patients with Pneumocystis jirovecii compared with those with candidiasis, aspergillosis, mucormycosis, and tuberculosis, and healthy volunteers","volume":"12","author":"Son","year":"2017","journal-title":"PLoS ONE."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood.V97.6.1604","article-title":"Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation","volume":"97","author":"Maertens","year":"2001","journal-title":"Blood."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1643068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:25:54Z","timestamp":1760419554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1643068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":64,"alternative-id":["10.3389\/fmed.2025.1643068"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1643068","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"article-number":"1643068"}}